Mostrar el registro sencillo del ítem
dc.contributor.author
Jaworski, Juan Pablo
dc.date.available
2021-06-30T20:47:08Z
dc.date.issued
2021-03-25
dc.identifier.citation
Jaworski, Juan Pablo; Monoclonal Antibody for Patients with Covid-19; Massachusetts Medical Society; New England Journal of Medicine; 384; 12; 25-3-2021; 1-2
dc.identifier.issn
0028-4793
dc.identifier.uri
http://hdl.handle.net/11336/135205
dc.description.abstract
The ACTIV-3/TICO LY-CoV555 Study Group (Dec. 22)1 hypothesized that low penetration of the antibody into the infected lungs might explain the lack of benefit of bamlanivimab (LY-CoV555) in hospitalized patients with coronavirus disease 2019 (Covid-19). However, we previously measured transudation of human immunodeficiency virus type 1 (HIV-1) monoclonal antibodies (VRC07-523 and PGT121) into tissues of 1-month-old rhesus macaques as part of a study to assess the effectiveness of monoclonal antibodies as postexposure prophylaxis.2 We detected high concentrations of passively transferred antibodies in the lungs of the two macaques (250 ng per milliliter in one and 285 ng per milliliter in the other) after subcutaneous administration of 10 mg per kilogram of body weight of monoclonal antibody cocktail. The concentration of antibody in the lungs was higher than the mean concentration detected in 26 other tissues (184 ng per milliliter); monoclonal antibody biodistribution was not affected by the virus in challenged animals.Our observations suggest that the rapid selection of neutralization-resistant variants, rather than biodistribution, might have undermined the efficacy of bamlanivimab in this trial. This hypothesis is supported by recent data provided by Regeneron about the preliminary efficacy of the combination of casirivimab and imdevimab in reducing the risk of death or mechanical ventilation in hospitalized patients with Covid-19.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Massachusetts Medical Society
dc.rights
info:eu-repo/semantics/restrictedAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
NEUTRALIZING ANTIBODIES
dc.subject
MONOCLONAL ANTIBODIES
dc.subject
THERAPY
dc.subject
COVID-19
dc.subject.classification
Virología
dc.subject.classification
Ciencias Biológicas
dc.subject.classification
CIENCIAS NATURALES Y EXACTAS
dc.subject.classification
Inmunología
dc.subject.classification
Medicina Básica
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.title
Monoclonal Antibody for Patients with Covid-19
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2021-06-29T13:25:49Z
dc.journal.volume
384
dc.journal.number
12
dc.journal.pagination
1-2
dc.journal.pais
Estados Unidos
dc.description.fil
Fil: Jaworski, Juan Pablo. Instituto Nacional de Tecnologia Agropecuaria. Centro de Investigacion En Ciencias Veterinarias y Agronomicas. Instituto de Virologia E Innovaciones Tecnologicas. - Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Pque. Centenario. Instituto de Virologia E Innovaciones Tecnologicas.; Argentina
dc.journal.title
New England Journal of Medicine
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/http://www.nejm.org/doi/10.1056/NEJMc2100221
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1056/NEJMc2100221
Archivos asociados